Outcomes After Switching to Faricimab for Refractive Macular Edema in Treatment-Experienced Eyes with Neovascular Age-Related Macular Degeneration.

Clinical ophthalmology (Auckland, N.Z.) Pub Date : 2024-10-29 eCollection Date: 2024-01-01 DOI:10.2147/OPTH.S483563

Yaqoob Qaseem, Kirk Kohwa Hou, Moritz S Pettenkofer

{"title":"Outcomes After Switching to Faricimab for Refractive Macular Edema in Treatment-Experienced Eyes with Neovascular Age-Related Macular Degeneration.","authors":"Yaqoob Qaseem, Kirk Kohwa Hou, Moritz S Pettenkofer","doi":"10.2147/OPTH.S483563","DOIUrl":null,"url":null,"abstract":"Purpose: To examine response to faricimab in neovascular age-related macular degeneration (nARMD) refractory to traditional anti-vascular endothelial growth factor (anti-VEGF) agents.Patients and methods: Retrospective chart review was conducted on eyes with nARMD with persistent subretinal and/or intraretinal fluid despite previously receiving ≥15 injections with ≥2 different anti-VEGF agents. Best corrected visual acuity (BCVA) and optical coherence tomography (OCT) parameters were collected at baseline, initial post-injection visit, and most recent visit with OCT following last faricimab.Results: Nineteen eyes were included. Average logMAR BCVA was 0.47 ± 0.60 at baseline, 0.42 ± 0.47 at initial follow-up (p=0.38), and 0.51 ± 0.63 at final visit (p = 0.50). Average central subfield thickness (CST) was 310 ± 92 μm at baseline, 279 ± 88 μm at initial follow-up (p = 0.001), and 274 ± 100 μm at last visit (p < 0.001). 9 eyes (47%) achieved resolution of fluid at both initial and final follow-up visits.Conclusion: Faricimab mildly decreased CST and reduced fluid in some nARMD eyes refractory to traditional anti-VEGF agents but had minimal effect on BCVA.","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11533168/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ophthalmology (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OPTH.S483563","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To examine response to faricimab in neovascular age-related macular degeneration (nARMD) refractory to traditional anti-vascular endothelial growth factor (anti-VEGF) agents.

Patients and methods: Retrospective chart review was conducted on eyes with nARMD with persistent subretinal and/or intraretinal fluid despite previously receiving ≥15 injections with ≥2 different anti-VEGF agents. Best corrected visual acuity (BCVA) and optical coherence tomography (OCT) parameters were collected at baseline, initial post-injection visit, and most recent visit with OCT following last faricimab.

Results: Nineteen eyes were included. Average logMAR BCVA was 0.47 ± 0.60 at baseline, 0.42 ± 0.47 at initial follow-up (p=0.38), and 0.51 ± 0.63 at final visit (p = 0.50). Average central subfield thickness (CST) was 310 ± 92 μm at baseline, 279 ± 88 μm at initial follow-up (p = 0.001), and 274 ± 100 μm at last visit (p < 0.001). 9 eyes (47%) achieved resolution of fluid at both initial and final follow-up visits.

Conclusion: Faricimab mildly decreased CST and reduced fluid in some nARMD eyes refractory to traditional anti-VEGF agents but had minimal effect on BCVA.

查看原文本刊更多论文

治疗经验丰富的新生血管性老年性黄斑变性患者改用法利单抗治疗屈光性黄斑水肿后的疗效。

目的：研究对传统抗血管内皮生长因子（anti-VEGF）药物难治的新生血管性年龄相关性黄斑变性（nARMD）患者对法尼单抗的反应：对之前接受过≥15次≥2种不同抗血管内皮生长因子药物注射但仍有持续性视网膜下和/或视网膜内积液的nARMD患者进行回顾性病历审查。在基线、注射后首次就诊和最后一次使用法尼单抗后的最近一次就诊中收集最佳矫正视力（BCVA）和光学相干断层扫描（OCT）参数：结果：共纳入 19 只眼睛。基线时 BCVA 平均对数为 0.47 ± 0.60，首次随访时为 0.42 ± 0.47（P=0.38），最后一次随访时为 0.51 ± 0.63（P=0.50）。基线时中央子野平均厚度（CST）为 310 ± 92 μm，首次随访时为 279 ± 88 μm（p = 0.001），最后一次随访时为 274 ± 100 μm（p < 0.001）。9只眼睛（47%）在首次和最后一次随访时积液均已消除：结论：法利西单抗可轻度降低CST，减少一些对传统抗血管内皮生长因子药物难治的nARMD眼的积液，但对BCVA的影响甚微。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical ophthalmology (Auckland, N.Z.)

CiteScore

4.10

自引率

0.00%

发文量